ANN ARBOR, Mich., April 21 /PRNewswire/ -- Ann Arbor-based Genetics Squared announced today the addition of Randal Charlton to its board of directors. Charlton brings his expertise and leadership in the area of drug discovery and technology development to the company that uses its patented evolutionary drug development(TM) software and methods to rescue promising but struggling compounds from clinical and market failure.
"Genetics Squared is very pleased to welcome Randal to the board of directors," said Bill Worzel, Genetics Squared's founder and chairman of the board. "Randal has been a friend of the company for some time now and Genetics Squared is delighted to formalize his contribution. He brings decades of experience in leading technology and life science companies, which he shares generously, and a wonderfully pragmatic point-of-view."
Charlton is the CEO of Asterand, the Detroit-based human tissue bank that provides research material to the world's leading drug discovery companies. Charlton's career has been spent developing new technology in a business environment. Prior to Asterand, he worked for genetics companies in Europe as well as technology companies in the United States.
"Genetics Squared's exceptional scientific team and unique technology promises to dramatically improve the cost and effectiveness of drug development," said Charlton. "I look forward to working with the company's management to ensure we realize that promise."
In addition to Bill Worzel, Charlton joins on Genetics Squared's board of directors, Tom Everist, founder and president of The Everist Company; Wassim Mourtada, managing director of CrystalPoint Partners; and John Freshley, president and CEO of Genetics Squared.
About Genetics Squared
Founded in 2002, Genetics Squared is an emerging biotechnology company focused on delivering the promise of personalized medicine. Using its patented evolutionary drug development(TM) technology and methods, Genetics Squared is able to "rescue" promising, but struggling compounds from clinical and market failure. The company's novel analytical approach discovers profiles of therapeutic responders and non-responders or those most likely to experience serious adverse events based on medical history, patient demographics, genetic and protein biomarkers. This allows the company and its service clients to target these promising therapies at the patients most likely to benefit. For more information, please visit http://www.genetics2.com/ .
CONTACT: Jessica Annaloro of Eiler Communications, +1-734-761-3399,Jessica@EilerPR.com , for Genetics Squared